Immuno-Oncology | Specialty

Nivolumab Improves Survival in Phase III RCC Trial

July 20th 2015

The phase III CheckMate-025 trial has been halted after an independent panel determined that nivolumab improved overall survival versus everolimus in patients with advanced renal cell carcinoma.

Dr. Nanda on Immunotherapy in Metastatic TNBC

July 18th 2015

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the efficacy of pembrolizumab and atezolizumab for the treatment of patients with metastatic triple-negative breast cancer.

FDA Grants Peptide Vaccine Orphan Status for Ovarian Cancer

July 17th 2015

The FDA has granted an orphan drug designation to the immunotherapy DPX-Survivac as a treatment for women with ovarian cancer.

Global Perspective on the ASCO Annual Meeting

July 16th 2015

New Agents for Refractory Metastatic Colorectal Cancer

July 16th 2015

Immunotherapy in Colorectal Cancer

July 16th 2015

Maintenance Therapy in Colorectal Cancer

July 16th 2015

EGFR Inhibition in RAS Wild-Type Unresectable mCRC

July 16th 2015

Daily Aspirin for Colorectal Cancer Prevention

July 16th 2015

Impact of the SIRFLOX Study on CRC Management

July 16th 2015

Role of Surgery in Metastatic Colorectal Cancer

July 16th 2015

Broad Molecular Profiling in Colorectal Cancer

July 16th 2015

Genetic Testing in Colorectal Cancer

July 16th 2015

PD-1 Blockade Effective in Mismatch Repair-Deficient CRC

July 15th 2015

James J. Lee, MD, PhD, discusses research into mismatch repair deficiency as a biomarker for PD-1 inhibition in colorectal cancer.

Dr. Bang on Pembrolizumab for Advanced Gastric Cancer

July 15th 2015

Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

Atezolizumab Achieves Primary Endpoint in Pivotal Phase II Bladder Cancer Study

July 13th 2015

Second-line treatment with atezolizumab (MPDL3280A) has met the primary endpoint of a pivotal phase II study by effectively shrinking tumors in patients with locally advanced or metastatic urothelial bladder cancer.

Adding Atezolizumab to Chemotherapy Shows Promise in NSCLC

July 10th 2015

Stephen Liu, MD, discusses the results and purpose of the uniquely designed trial examining atezolizumab in combination with platinum-based doublet chemotherapy in treatment-naïve patients with advanced non–small cell lung cancer.

How a Rebellious Scientist Helped Launch the Modern Age of Immunotherapy

July 5th 2015

James P. Allison, PhD, was honored in the Scientific Advances category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

New Agents Show Promise in Gastric Cancer

July 3rd 2015

Josep Tabernero, MD, PhD, summarized novel agents that are currently under exploration for patients with gastric cancer.

Immunotherapy in Melanoma: What Does the Future Hold?

June 25th 2015

Howard L. Kaufman, MD, discusses the rapidly advancing immunotherapy armamentarium in melanoma.